The year's new drugs and biologics 2020
Drugs Today (Barc). 2021 Feb;57(2):101-177. doi: 10.1358/dot.2021.57.2.3275929.ABSTRACT2020 will go down in history as a year marked in every respect by the emergence and astonishingly rapid spread of the first major global viral pandemic in a century. It seems like nearly every event or story of the year was influenced in some way by COVID-19, and in that respect, the year ended on a high note with the authorization for emergency use of the first vaccines to prevent SARS-CoV-2 infection and drugs to treat COVID-19. Despite the pandemic's dominance of the 2020 headlines, productivity was at a record high level across all therapeutic areas, as seen by the number of products in this year's review: approximately 50% more than the previous year. Notable achievements include the launch of the first treatment for hepatitis D; regulatory decisions on a suite of biologics for the prevention and treatment of Ebola virus disease, fruit of the 2016-2018 outbreak in the Democratic Republic of Congo; the approval of the first-ever drug to treat Hutchinson-Gilford progeria syndrome, a rare genetic disorder that leads to premature aging; the first treatment developed specifically for thyroid eye disease, also known as Graves' ophthalmopathy; the first nonhormonal, on-demand, vaginal pH-regulating contraceptive; and the first oral allergen immunotherapy for peanut allergy.PMID:33656016 | DOI:10.1358/dot.2021.57.2.3275929
Source: Drugs of Today - Category: Drugs & Pharmacology Authors: A I Graul L A Sorbera Source Type: research
More News: Allergy | Allergy & Immunology | Congo Health | COVID-19 | Drugs & Pharmacology | Ebola | Ebola Vaccine | Emergency Medicine | Fruit | Genetics | Hepatitis | Hepatitis Vaccine | Immunotherapy | Opthalmology | Outbreaks | Pandemics | Peanuts | SARS | Thyroid | Vaccines